Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
NCT01227668Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Aripiprazole with Placebo (2 arms). Primary endpoint: Percentage of Patients Relapsing at 16 weeks. Started Mar 2011; status: completed.
02
Drugs
aripiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01227668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227668.